Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03313778
Title Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603)
Acronym KEYNOTE-603
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors ModernaTX, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Arizona ACTIVE_NOT_RECRUITING Tucson Arizona 85721 United States Details
Florida Cancer Specialists RECRUITING Sarasota Florida 34232 United States Details
H Lee Moffitt Cancer Center and Research Institute RECRUITING Tampa Florida 33612-9416 United States Details
Massachusetts General Hospital ACTIVE_NOT_RECRUITING Boston Massachusetts 02114 United States Details
John Theurer Cancer Center ACTIVE_NOT_RECRUITING Hackensack New Jersey 07601 United States Details
NYU Langone RECRUITING New York New York 10016 United States Details
Duke Cancer Institute ACTIVE_NOT_RECRUITING Durham North Carolina 27710 United States Details
The Cleveland Clinic Foundation ACTIVE_NOT_RECRUITING Cleveland Ohio 44195-0001 United States Details
Providence Portland Medical Center WITHDRAWN Portland Oregon 97213-2933 United States Details
Sarah Cannon Research Institute, Tennessee Oncology ACTIVE_NOT_RECRUITING Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field